Merck KGaA to invest 80 million euros in China pharma production

15 November 2013

Germany’s Merck KGaA (MRK: DE) said this morning (November 15) that it plans to invest 80 million euros ($106.8 million) in a new pharmaceutical manufacturing facility in China, to be located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region.

“This further investment in China reflects Merck’s long-term commitment to the country where our group has been present for 80 years,” said Belen Garijo, president and chief executive of Merck Serono, the biopharmaceutical division of Merck.

The new facility will focus on the bulk production and packaging of Glucophage (metformin), the beta-blocker Concor (bisoprolol) and Euthyrox (levothyroxine), Merck’s leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK